Why Axsome Therapeutics Stock Is Back in Focus After the Latest FDA Milestone

Axsome Therapeutics (AXSM) is drawing fresh attention after the U.S. Food and Drug Administration accepted its New Drug Application for AXS-12, an investigational treatment for cataplexy in narcolepsy, and set a PDUFA target action date of May 1, 2027.

For investors, the FDA’s acceptance of AXS-12 comes as Axsome Therapeutics’ share price has risen 29.6% over the past 90 days and delivered a 139.02% total shareholder return over the past year. This suggests momentum has been building around the broader pipeline story.

If this kind of move has your attention, it could be a good moment to look across the sector and see what else is gaining traction in healthcare and neurology focused AI, starting with 39 healthcare AI stocks

After a 139.02% total return in a year and a fresh FDA milestone for AXS-12, investors are facing a simple tension: pay up for Axsome Therapeutics’ momentum today, or wait in hope of a cheaper entry as the valuation picture comes into focus.

Most Popular Narrative: 15% Undervalued

Axsome Therapeutics last closed at $241, while the most followed narrative argues fair value sits at $282.51, framing the recent FDA milestone against an already ambitious financial roadmap.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications). This pipeline positions Axsome to potentially benefit from the aging population and rising prevalence of CNS disorders. If successful, these efforts could contribute to a more diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Want to see what kind of revenue curve and profit profile would need to materialize for that fair value to stack up? The most popular narrative focuses on sharp top line expansion, a swing from losses to sizeable earnings, and a premium future earnings multiple that is usually reserved for mature leaders in their industries. Curious how those moving parts fit together across the next few years and which assumptions carry the most weight in the model?

Result: Fair Value of $282.51 (UNDERVALUED)

However, Axsome Therapeutics still carries meaningful execution risk, with reliance on Auvelity and Sunosi for most revenue and ongoing net losses that could increase funding needs.

Another View: Axsome Therapeutics Through a Sales Multiple Lens

While the most followed Axsome Therapeutics narrative leans on future cash flows and earnings power, the current P/S ratio of 17.5x paints a different picture. That is far above the US Pharmaceuticals industry at 6.1x and the peer average of 5.2x, yet very close to a fair ratio of 17.8x, which the market could move toward over time. For you, the question is whether this gap points to stretched expectations on today’s revenue base or a price that already bakes in much of the growth story.

Next Steps

If the mixed signals around Axsome Therapeutics leave you undecided, this may be a good time to review the numbers yourself and consider the potential upside investors are watching with 2 key rewards

Looking For More Investment Ideas Beyond Axsome Therapeutics?

Before moving on from Axsome Therapeutics, give yourself a broader view of the market by scanning for other stocks that match the kind of opportunities you care about most.

• Spot potential bargains early by reviewing companies that screen as screener containing 20 high quality undiscovered gems before they appear on everyone else’s radar.
• Strengthen your core holdings by focusing on businesses highlighted in the solid balance sheet and fundamentals stocks screener (49 results) to support a more resilient portfolio.
• Reduce portfolio stress by tilting toward companies surfaced in the 81 resilient stocks with low risk scores that may offer a steadier ride through market swings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.